Leukaemia (all types): lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Screening, prevention and diagnosis	1
Special situations	1
Other settings	1

Screening, prevention and diagnosis

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Diagnosis	Blood count and film, bone marrow aspirate and biopsy, flow cytometry, cytogenetics and molecular panel; the subtype then sets the pathway.	Multiparameter flow cytometry MRDCytogenetics and FISH		95

Special situations

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Supportive care	Growth factor support, transfusion, infection prevention and tumour lysis prophylaxis around intensive treatment.	Growth factors: G-CSF and febrile neutropenia preventionTransfusion support and anaemia management		90

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Treatment	By type on the subtype pages: intensive chemotherapy and transplant for acute leukaemias, tyrosine kinase inhibitors for CML, BTK and BCL2 inhibitors for CLL.	Acute lymphoblastic leukaemiaAcute myeloid leukaemiaChronic lymphocytic leukaemiaChronic myeloid leukaemia (CML)		-

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.